What is the share price of Nureca Ltd (NURECA) today?
The share price of NURECA as on 7th October 2026 is ₹333.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Nureca Ltd (NURECA) share?
The past returns of Nureca Ltd (NURECA) share are- Past 1 week: -5.94%
- Past 1 month: 3.47%
- Past 3 months: 46.76%
- Past 6 months: 39.96%
- Past 1 year: 42.03%
- Past 3 years: -11.08%
- Past 5 years: -83.18%
What are the peers or stocks similar to Nureca Ltd (NURECA)?
The peers or stocks similar to Nureca Ltd (NURECA) include:What is the market cap of Nureca Ltd (NURECA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Nureca Ltd (NURECA) is ₹323.04 Cr as of 7th October 2026.What is the 52 week high and low of Nureca Ltd (NURECA) share?
The 52-week high of Nureca Ltd (NURECA) is ₹376 and the 52-week low is ₹204.What is the PE and PB ratio of Nureca Ltd (NURECA) stock?
The P/E (price-to-earnings) ratio of Nureca Ltd (NURECA) is 156.06. The P/B (price-to-book) ratio is 1.79.Which sector does Nureca Ltd (NURECA) belong to?
Nureca Ltd (NURECA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Nureca Ltd (NURECA) shares?
You can directly buy Nureca Ltd (NURECA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Nureca Ltd
NURECA Share Price
NSENURECA Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
NURECA Performance & Key Metrics
NURECA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 75.13 | 1.79 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 45.85 | 5.74 | 0.50% |
NURECA Analyst Ratings & Forecast
Price Upside
Earnings Growth
Rev. Growth
NURECA Company Profile
Nureca Ltd is engaged in the marketing of home healthcare & wellness products
NURECA Forecast
NURECA Forecasts
NURECA
NURECA
Income
Balance Sheet
Cash Flow
NURECA Income Statement
NURECA Income Statement
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 15.71 | 26.06 | 34.36 | 27.94 | 33.73 | 36.75 | 40.06 | 41.83 | 36.42 | 42.16 | ||||||||||
| Operating & Other expenses | 21.40 | 22.64 | 33.55 | 30.48 | 30.54 | 34.74 | 34.47 | 36.39 | 41.19 | 36.92 | ||||||||||
| EBITDA | -5.69 | 3.42 | 0.81 | -2.54 | 3.19 | 2.01 | 5.59 | 5.44 | -4.77 | 5.24 | ||||||||||
| Depreciation/Amortization | 0.60 | 0.66 | 0.62 | 0.54 | 0.52 | 0.53 | 0.54 | 0.50 | 0.45 | 0.61 | ||||||||||
| PBIT | -6.29 | 2.76 | 0.19 | -3.08 | 2.67 | 1.48 | 5.05 | 4.94 | -5.22 | 4.63 | ||||||||||
| Interest & Other Items | 0.18 | 0.15 | 0.27 | 0.18 | 0.62 | 0.25 | 0.46 | 0.28 | 0.30 | 0.20 | ||||||||||
| PBT | -6.47 | 2.61 | -0.08 | -3.26 | 2.05 | 1.23 | 4.59 | 4.66 | -5.52 | 4.43 | ||||||||||
| Taxes & Other Items | -2.32 | 0.96 | 0.41 | -0.45 | -0.41 | 0.42 | 0.97 | 0.93 | 0.59 | 1.37 | ||||||||||
| Net Income | -4.15 | 1.65 | -0.49 | -2.81 | 2.46 | 0.81 | 3.62 | 3.73 | -6.11 | 3.06 | ||||||||||
| EPS | -4.15 | 1.66 | -0.48 | -2.80 | 2.47 | 0.81 | 3.63 | 3.91 | -6.45 | 3.21 |
NURECA Company Updates
NURECA Stock Peers
NURECA Past Performance & Peer Comparison
NURECA Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Nureca Ltd | 156.06 | 1.79 | — |
| Sun Pharmaceutical Industries Ltd | 37.71 | 5.16 | 0.89% |
| Torrent Pharmaceuticals Ltd | 83.90 | 10.32 | 0.71% |
| Zydus Lifesciences Ltd | 22.95 | 3.91 | 0.09% |
NURECA Stock Price Comparison
Compare NURECA with any stock or ETFNURECA Holdings
NURECA Shareholdings
NURECA Promoter Holdings Trend
NURECA Promoter Holdings Trend
In last 6 months, promoter holding in the company has increased by 3.12%
Pledged promoter holdings is insignificant
NURECA Institutional Holdings Trend
NURECA Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
NURECA Shareholding Pattern
NURECA Shareholding Pattern
NURECA Shareholding History
NURECA Shareholding History
smallcases containing NURECA stock
smallcases containing NURECA stock
Looks like this stock is not in any smallcase yet.
NURECA Events
NURECA Events
NURECA Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
NURECA Dividend Trend
No dividend trend available
NURECA Upcoming Dividends
NURECA Upcoming Dividends
No upcoming dividends are available
NURECA Past Dividends
NURECA Past Dividends
Cash Dividend
Ex DateEx DateFeb 24, 2022
Dividend/Share
₹3.00
Ex DateEx Date
Feb 24, 2022
Cash Dividend
Ex DateEx DateSep 21, 2021
Dividend/Share
₹2.00
Ex DateEx Date
Sep 21, 2021
NURECA Stock News & Opinions
NURECA Stock News & Opinions
Nureca Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company's equity shares will be closed from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half-year ending September 30, 2026, prohibiting trading for designated persons and their immediate relatives.
Net profit of Nureca rose 279.01% to Rs 3.07 crore in the quarter ended June 2026 as against Rs 0.81 crore during the previous quarter ended June 2025. Sales rose 18.02% to Rs 40.34 crore in the quarter ended June 2026 as against Rs 34.18 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales40.3434.18 18 OPM %8.48-1.64 - PBDT5.041.76 186 PBT4.431.23 260 NP3.070.81 279 Powered by Capital Market - Live
Nureca will hold a meeting of the Board of Directors of the Company on 21 July 2026.
Hinduja Global Solutions Ltd, Wanbury Ltd, Fino Payments Bank Ltd and Orient Technologies Ltd are among the other gainers in the BSE's 'B' group today, 14 July 2026.Nureca Ltd surged 13.94% to Rs 280.3 at 12:01 IST. The stock was the biggest gainer in the BSE's 'B' group. On the BSE, 21770 shares were traded on the counter so far as against the average daily volumes of 1218 shares in the past one month. Hinduja Global Solutions Ltd soared 12.99% to Rs 471.05. The stock was the second biggest gainer in 'B' group. On the BSE, 28493 shares were traded on the counter so far as against the average daily volumes of 10936 shares in the past one month. Wanbury Ltd spiked 12.62% to Rs 338.7. The stock was the third biggest gainer in 'B' group. On the BSE, 2.14 lakh shares were traded on the counter so far as against the average daily volumes of 12946 shares in the past one month. Fino Payments Bank Ltd jumped 11.61% to Rs 179.7. The stock was the fourth biggest gainer in 'B' group. On the BSE, 19.54 lakh shares were traded on the counter so far as against the average daily volumes of 98421 shares in the past one month. Orient Technologies Ltd advanced 11.54% to Rs 288.95. The stock was the fifth biggest gainer in 'B' group. On the BSE, 2.63 lakh shares were traded on the counter so far as against the average daily volumes of 18896 shares in the past one month. Powered by Capital Market - Live
Nureca announced that the 10th Annual General Meeting(AGM) of the company will be held on 28 July 2026.
Net loss of Nureca reported to Rs 6.09 crore in the quarter ended March 2026 as against net profit of Rs 2.47 crore during the previous quarter ended March 2025. Sales rose 11.56% to Rs 35.41 crore in the quarter ended March 2026 as against Rs 31.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 144.71% to Rs 2.08 crore in the year ended March 2026 as against Rs 0.85 crore during the previous year ended March 2025. Sales rose 34.01% to Rs 146.96 crore in the year ended March 2026 as against Rs 109.66 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales35.4131.74 12 146.96109.66 34 OPM %-16.323.78 -0.12-6.88 - PBDT-5.062.57 PL 7.003.68 90 PBT-5.512.05 PL 4.981.34 272 NP-6.092.47 PL 2.080.85 145 Powered by Capital Market - Live
Nureca will hold a meeting of the Board of Directors of the Company on 29 May 2026.
Net profit stood at Rs 3.73 crore in Q3 FY26, compared with a loss of Rs 2.80 crore in Q3 FY25. On a sequential basis, PAT rose 2.8% from Rs 3.63 crore in Q2 FY26. Revenue from operations jumped 49.8% YoY to Rs 39.64 crore in Q3 FY26 from Rs 26.46 crore a year ago. Sequentially, revenue increased 5.0% from Rs 37.74 crore in Q2 FY26. Profit before tax stood at Rs 4.66 crore in Q3 FY26, compared with a loss of Rs 3.25 crore in the year-ago quarter, and was broadly flat sequentially versus Rs 4.60 crore in Q2 FY26. Total expenditure rose 19.4% YoY to Rs 36.39 crore during the quarter. Employee expenses increased 12.5% YoY to Rs 4.32 crore, while raw material costs surged 158.50% to Rs 10.34 crore from Rs 4.0 crore last year. Interest expense rose 55.56% YoY to Rs 0.28 crore from Rs 0.18 crore, while depreciation eased 7.4% YoY to Rs 0.50 crore. The management stated that the financial performance was primarily driven by enhanced operational efficiencies, improved sourcing strategies, and strengthened manufacturing capabilities. Focused cost optimization, tighter supply chain controls, and productivity improvements enabled better margins, while scalable manufacturing capabilities supported sustainable growth and consistent execution. Nureca continues to operate a digital-first, asset-light model, with over 90% of revenues generated through online channels. The company remains debt-free and maintains a healthy liquidity position. Nureca is a digital healthcare company focused on home healthcare and wellness products. Powered by Capital Market - Live
Net profit of Nureca reported to Rs 3.73 crore in the quarter ended December 2025 as against net loss of Rs 2.80 crore during the previous quarter ended December 2024. Sales rose 49.81% to Rs 39.64 crore in the quarter ended December 2025 as against Rs 26.46 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales39.6426.46 50 OPM %8.20-15.19 - PBDT5.16-2.71 LP PBT4.66-3.25 LP NP3.73-2.80 LP Powered by Capital Market - Live
Nureca will hold a meeting of the Board of Directors of the Company on 17 January 2026.Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of -6.44%, vs industry avg of 11.75%
Over the last 5 years, market share decreased from 0.07% to 0.03%
Over the last 5 years, net income has grown at a yearly rate of -46.31%, vs industry avg of 10.44%